MonoSol Rx, LLC Granted US Patent for Thin Film Manufacturing Process
WARREN, N.J. (Feb. 21, 2008) – MonoSol Rx, a drug delivery company specializing in quick dissolving thin film pharmaceutical products, today announced that it has been granted U.S. patent No. 7,357,891 from the United States Patent and Trademark Office (USPTO). The patent, which is expected to issue on April 15, 2008, relates to the Company’s proprietary mixing system technology and controlled film drying process.
of this patent is a significant milestone for MonoSol Rx as it
validates and protects our thin film drug delivery technology. As we
strive to expand the patent protection of our thin film technology,
this milestone serves to fortify our leadership position in the
delivery of prescription drugs using thin film” said A. Mark Schobel,
president and chief executive officer of MonoSol Rx. “Our proprietary
mixing and drying processes enable us to maintain precise content
uniformity of the drug, incorporate
taste-masked drug encapsulations, and allow the manufacture of sensitive drug targets that may otherwise not be possible. Each of these factors, combined with the convenience and dosing benefits of thin film, are key to the success of our technology, and help to differentiate MonoSol Rx from similar thin film offerings and other modes of drug delivery.”
The patent relates to MonoSol Rx’s Dual Integrated Mixing System. This patented mixing process is designed to provide a continuous batch coating of a drug contained in the film to ensure product uniformity while delivering consistent organoleptic performance throughout the film manufacturing process.
Also encompassed in the patent is MonoSol Rx’s controlled film drying process. This controlled drying process is critical to maintaining content uniformity of a drug within the film thereby ensuring accurate and predictable dosing for patients.
Mr. Schobel also said, “This is an important acknowledgement of the innovative technology that MonoSol Rx has developed for thin film drug delivery. We are committed to pursuing and developing technology that provides significant advantages for MonoSol Rx and its development partners.”
About MonoSol Rx
MonoSol Rx is a drug delivery company specializing in proprietary, dissolving thin film pharmaceutical products. The Company’s thin film technology, which is similar in size, shape and thickness to a postage stamp, dissolves rapidly and utilizes a novel process and proprietary encapsulation compositions to mask the taste of the drug contained within the film. MonoSol Rx’s strategy is to develop and partner innovative thin film strip products in the prescription, generic and OTC pharmaceutical markets and to establish a leadership position in thin film drug delivery technology through continued development of its drug delivery technology and intellectual property portfolio.